

NETT NewsFlash

October 2012



Enrollment Update:
As of 10-31-12 at 10:00a (EDT)

ALIAS
ENROLLMENT
COMPLETE



point



Arizona	5	58	16	Not Active
Cincinnati	30	70	46	<5
Emory	28	64	22	5
HFH	12	12	33	Not Active
Kentucky	33	20	23	<5
Maryland	15	<5	19	<5
Mass General	-	Not Active	Not Active	Not Active
Minnesota	22	61	44	Not Active
NYP	32	<5	35	<5
Ohio State	-	Not Active	Not Active	Not Active
OHSU	58*	26	29	Not Active
Pittsburgh	-	Not Active	Not Active	Not Active
SUNY Downstate	-	Not Active	Not Active	Not Active
Stanford	26	62	33	<5
Temple	29	41	30	<5
Texas	36	61	35	<5
UCLA	-	Not Active	Not Active	Not Active
UCSF	25	18	22	<5
UPenn	42	46	105	<5
VCU	11	24	12	Not Active
Wayne State	33	15	66	<5
Wisconsin	15	64	16	<5
Emmes (POINT only)	-	-	572	-
Ancillary Sites (SHINE only)	-	-	-	18
TOTAL	452	649	1158	43

*OHSU WAS AN ORIGINAL SITE IN THE ALIAS I TRIAL AND CONTINUES IN THE ALIAS II TRIAL UNDER THE SAME CONTRACTUAL ARRANGEMENT WITH THE UNIVERSITY OF MIAMI STUDY CHAIR SITE.

POINT 1. When a new subject is randomized, please contact the **primary care physician (PCP)** to explain the subject is participating in POINT and should remain on study drug throughout the duration of the trial. If the PCP believes the study drug should be stopped, either temporarily or permanently, he/she should include the study team investigators in the decision-making process. Also, even if the study drug is stopped, the importance of continuing to follow the patient in the trial should be stressed.

2. When asking the **Questionnaire for Verifying Stroke Free Status (QVSFS)** to the subject and/or relative/caregiver/friend, please stress that the questions relate to events that occurred since last contact and should not include the event for which the subject was enrolled in the study.

- Aaron Perlmutter (perlmutt@umsc.edu)

NETT Network

Contact Us: nett-contact@umich.edu (734) 232-2142 Website: <http://nett.umich.edu>